Back HIV/AIDS

HIV / AIDS

AIDS 2014: Dolutegravir Demonstrates Good Efficacy Despite Resistance

Antiretroviral regimens containing the recently approved HIV integrase inhibitor dolutegravir (Tivicay) demonstrated high rates of viral suppression even in treatment-experienced people who were resistant to NRTIs. Among people starting treatment for the first time, no resistance was detected through 96 weeks, according to study findings presented at the 20th International AIDS Conference last week in Melbourne.

alt

AIDS 2014: iPrEx PrEP Users Talk Condoms, Pills, Anxiety, and Relief

Interviews with participants in the U.S. sites of the iPrEx study of pre-exposure prophylaxis (PrEP) show that participants who took it mainly used it as an additional source of reassurance rather than to replace whatever risk-management strategy they were currently using to avoid HIV infection, researchers reported at the 20th International AIDS Conference last week in Melbourne.

alt

AIDS 2014: Police Can Play a Role in Reducing HIV [VIDEO]

An increasing body of evidence indicates that police practices -- including confiscating condoms from sex workers, arresting people for using drugs, and persecuting gay men and transgender people -- can impede public health and discourage people from accessing crucial HIV prevention and care services.

alt

AIDS 2014: More Data Suggest Increased HIV Risk from Injectable Contraceptives

A sophisticated meta-analysis, pooling individual-level data on 37,000 women, has found that the use of DMPA injectable hormonal contraception is linked with a higher rate of new HIV infections among women, researchers reported at the 20th International AIDS Conference last week in Melbourne. However, the World Health Organization (WHO) announced at the same session that its guideline supporting the provision of this contraceptive to women at risk of HIV infection remains unchanged.

alt

AIDS 2014: Adult Male Circumcision Also Protects Women from HIV Infection [VIDEO]

Voluntary medical male circumcision -- which has been shown to reduce the risk of men acquiring HIV by around 50% -- also offers protection for their female partners, according to study findings presented Friday at the 20th International AIDS Conference taking place this week in Melbourne.

alt

UNAIDS Gap Report Finds Half of HIV+ People Worldwide Are Unaware of Status

Half of people living with HIV worldwide -- or approximately 19 million -- do not know they are infected, preventing them from receiving life-saving treatment and contributing to viral transmission, according to the latest UNAIDS Gap Report released in advance of the 20th International AIDS Conference last week in Melbourne. The report also outlines progress, including the 13 million people who had access to antiretroviral therapy at the end of 2013.

alt

AIDS2014: Efavirenz Use Not Linked to Neurocognitive Impairment, Study Finds

People who use antiretroviral regimens containing efavirenz (Sustiva, also in the Atripla coformulation) were not at higher risk for impaired neurocognitive function, either overall or when looking at specific functional domain, researchers reported this week at the 20th International AIDS Conference in Melbourne, Australia.

alt